MBRX

Moleculin Biotech, Inc.

Tremor tracks 1 of its cancer trials.

Company-wide warning signs

These add points to every one of this company's trials.

None right now.

Trials

MBRXMoleculin Biotech, Inc.
0Calm
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
Signing up patientsPhase 2/3312 patientsMain results: Aug 2029

Key executives leaving

From the last 12 months of the company's SEC reports.

None found.

Insider trades (last 6 months)

“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.

0 sales (0 not pre-planned) · 3 purchases

Foster Jonathan P.Chief Financial Officer · Aug 3, 2026Bought 293,333 shares
KLEMP WALTER VCEO and President · Aug 3, 2026Bought 533,333 shares
PICKER DONALD HChief Science Officer · Aug 3, 2026Bought 173,333 shares

Recent SEC filings

Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.

Money left

Coming soon: how many months of cash the company has, from its quarterly reports.